Search Bryan's.blog

Stocks

MSOS and MSOX: Cannabis Investors Are Tired of Waiting

MSOS and MSOX investors are still waiting for cannabis reform to deliver lasting results. With 7,000 MSOX shares at stake, I examine Trump’s Schedule III effort, the DEA delays, and why daily leverage makes an uncertain timeline especially costly.

By Bryan Published November 18, 2026
MSOS and MSOX: Cannabis Investors Are Tired of Waiting

By Bryan | November 18, 2026

Disclosure: I hold 7,000 shares of MSOX at an average cost of $5.60 per share, representing a $39,200 cost basis. Prices below are dated snapshots.

Cannabis investors have spent years waiting for Washington to deliver a breakthrough. Every announcement brings another reason to believe. Every procedural delay brings another reason to wonder whether the finish line is moving again.

For MSOX holders, waiting carries an additional risk. This fund has a daily leverage objective, and the path between the announcement and the outcome can matter enormously.

I am writing this as someone holding the position. My frustration is personal. That also means the criticism needs to be accurate.

Trump has not delivered the broad rescheduling resolution investors wanted. But saying he accomplished nothing, or that one judge twice struck down a completed nationwide reform, would misstate the record.

MSOS vs MSOX: The difference matters

MSOS provides actively managed exposure to U.S. cannabis companies. MSOX seeks approximately twice the daily total return of MSOS before fees and expenses, primarily through swaps. It does not promise twice the return over an investor’s entire holding period. Advisorshares

AdvisorShares’ published market price returns through October 31, 2026 show the difference:

FundYear to date return
MSOS−16.17%
MSOX−60.14%

These are the sponsor’s published performance figures. Advisorshares

Believing cannabis businesses will eventually benefit from reform and choosing a daily leveraged fund are two separate investment decisions.

My MSOX position makes the damage concrete

Using the November 17 closing price of $1.48, my stated position would look like this. stockanalysis.com

Position measureAmount
Shares7,000
Average cost$5.60
Cost basis$39,200
Value at $1.48$10,360
Unrealized loss$28,840
Decline from cost73.6%
Gain needed to reach $5.60278.4%

Calculations assume the stated share count and basis are current and adjusted for corporate actions, excluding distributions, fees, and taxes.

A strong rally and a recovery to my entry price are very different things. Even doubling from $1.48 would only reach $2.96.

My purchase price explains my exposure. It does not determine what the fund should be worth today.

What Trump actually did on Schedule III

On December 18, 2025, Trump signed an executive order directing the Attorney General to complete marijuana rescheduling as quickly as federal law allowed. The executive order itself did not reschedule marijuana. The White House

In April 2026, the administration took a material but limited step. DOJ announced Schedule III treatment for FDA approved marijuana products and marijuana covered by qualifying state medical licenses. It separately initiated an expedited hearing process for broader rescheduling. United States Department of Justice

Limited medical reform is real progress. It is also different from completing broader reform across the industry.

The fair criticism is that the promise of speed has not produced the broad, settled outcome investors anticipated. Announcements change expectations immediately. Implementation and litigation operate on a different timetable.

Which judge delayed rescheduling?

There are different proceedings and different judges in this story.

John Mulrooney handled the older case. In January 2025, he allowed an interlocutory appeal that delayed proceedings. That happened before Trump’s January 20 inauguration.

The dispute included allegations of improper communications involving DEA personnel and outside actors. Mulrooney’s January 15 transmittal explicitly said those factual allegations had not been tested through testimony and that no facts had been found. dea.gov

By July, the appeal remained pending with the DEA Administrator. Mulrooney announced his retirement effective August 1, warning that it would leave DEA without an administrative law judge for these matters. dea.gov

That history raises questions about agency management. It does not establish that Mulrooney sabotaged Trump’s later executive order.

Derek Julius handled the replacement hearing. Those proceedings ran from June 29 through July 15, 2026. dea.gov

On September 29, Julius stayed proceedings while considering opponents’ request to introduce a new Government Accountability Office report. themarijuanaherald.com

On October 22, he admitted the report and allowed limited written briefing. Crucially, he denied the request to reopen the hearing for additional testimony.

His order set November 5 as the reply deadline and said the stay would expire when briefing concluded unless otherwise ordered. dea.gov

Those September and October actions prolonged the process. They were not two final rulings rejecting Schedule III. November 5 was also not a deadline for delivering a final rule.

I did not locate a subsequent final nationwide rule or later recommended decision in the materials reviewed for this article.

Is anything nefarious happening?

There are documented allegations worth scrutinizing. There is not enough evidence in the material reviewed to accuse either judge of corruption, a financial conflict, or market manipulation.

The GAO report identified shortcomings in written agency policies and procedures. It recommended clearer responsibilities and more consistent processes. That is meaningful oversight, but it is not a finding that cannabis cannot qualify for Schedule III. U.S. GAO

The government’s November 5 reply argued that the report should receive no weight in deciding this rescheduling matter. That is the government’s position, not an adjudicated conclusion. themarijuanaherald.com

Giving opponents additional briefing time can be frustrating without proving improper motives. Julius’ refusal to reopen the hearing also complicates a claim that he simply granted opponents everything they wanted.

Investors can reasonably demand a transparent timetable without inventing a conspiracy.

MSOX has a documented accounting problem worth questioning

On March 6, AdvisorShares announced a NAV restatement because the fund administrator had incorrectly accounted for income accruals on certain swaps held between December 22, 2025 and February 2, 2026.

For February 2, the disclosed NAV changed from $3.23646 to $3.20382, a reduction of roughly 1 percent.

AdvisorShares said enhanced controls had been implemented and auditors notified. Its release attributed responsibility to the administrator and disclaimed liability. Advisorshares

This correction does not explain the fund’s entire decline or establish fraud. It does justify asking:

  • When was the error discovered?
  • Did affected transactions require remediation?
  • How was the effectiveness of the new controls verified?

Those are concrete questions supported by the sponsor’s own disclosure.

Why waiting can hurt MSOX

Consider an idealized example before expenses and tracking differences:

InvestmentStartAfter benchmark rises 10%After benchmark falls 9.09%
Benchmark$100$110About $100
2x daily exposure$100$120About $98.18

The benchmark returns to its starting point. The leveraged position does not.

Compounding can also help during a persistent favorable trend. Loss is not automatic in every holding period. But repeated reversals can make waiting expensive.

That is why I built Leverage Lab. Compare the flat but choppy and steady climb scenarios to see how different paths change the outcome.

The simulator illustrates mechanics. It does not predict MSOX returns or reproduce every actual fund cost.

The sector is more than a Washington trade

Schedule III matters financially. Treasury explained that Section 280E generally bars deductions and credits for businesses trafficking in Schedule I or II substances. Medical rescheduling can remove that barrier for qualifying activities, although mixed activities and implementation details matter. U.S. Department of the Treasury

But tax reform cannot substitute for operating performance.

Green Thumb reported Q3 revenue of $324.4 million, up 11.3 percent, and $58.3 million of operating cash flow, alongside a $4.8 million GAAP net loss. Trulieve reported $230 million in quarterly revenue and $183 million of operating cash flow over the first nine months. sec.gov

Those figures undermine the idea that every cannabis business is simply failing.

Investors still need to assess debt, cash taxes, capital spending, share issuance, and sustainable cash flow company by company.

What cannabis investors deserve now

Washington should clearly explain the remaining process. Fund sponsors should make leverage risks and operational corrections easy to understand. Company management teams should demonstrate what reform means for cash flow per share.

For me, the hard question is whether a daily leveraged product fits a thesis dependent on an uncertain political timetable.

I remain exposed through the position disclosed above. That is a financial interest, not evidence that recovery is guaranteed.

Cannabis investors have heard enough about the next catalyst. What matters now is completed policy, credible reporting, and results that reach shareholders.

Written by

Bryan

Independent technology coverage focused on useful context, real-world experience, and honest recommendations.